Nipah Patient Receives Second Monoclonal Antibody Dose

A patient infected with the Nipah virus has been administered a second dose of a monoclonal antibody treatment. The drug is part of an experimental therapy aimed at combating the virus. This follows initial treatment that showed some positive response. Health officials are monitoring the patient's condition closely. The Nipah virus is known for causing severe illness and has a high mortality rate. This treatment approach is being evaluated for its effectiveness. The case highlights ongoing efforts to manage outbreaks of the virus.

It underscores the development of potential treatments for a deadly and emerging viral disease.